Nkarta (NKTX) Revenue (2019)
Nkarta (NKTX) recorded quarterly Revenue of -$385.0 in Q3 2019, down 116.68% quarter-over-quarter from $2308.0 in Q2 2019.
Nkarta (NKTX) Revenue (2019) Analysis & Trends
Nkarta's Revenue history runs 1 years deep, the most recent figure standing at -$385.0 for Q3 2019.
- In Q3 2019, Revenue changed N/A year-over-year to -$385.0; the TTM figure through Dec 2020 stood at -$385.0 (changed N/A YoY), while the FY2019 annual figure was $115000.0, changed N/A from the prior year.
- Revenue was -$385.0 for Q3 2019 at Nkarta, down from $2308.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $2308.0 in Q2 2019 to a low of -$385.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Nkarta | 210.52 Mn | 210.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | -385.00 |
| Jun 30, 2019 | 2,308.00 |